Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy.

14 , 15 In these people, disproportion adipose distribution (tending towards central and visceral adiposity) and adipose dysfunction, sarcopaenia and early beta cell failure are likely to be significant drivers of MASLD and T2D development. 12 – 14 As a result of the linked pathophysiologies, MASLD is extremely common in patients with T2D, with prevalence demonstrated to be as high as 65–70%, and studies using liver biopsy-based diagnosis demonstrating prevalence of over 90%. 16 – 18 In addition, there is a bi-directional, synergistic interaction between the conditions, which leads to worsening diabetes control, increased risk of MASLD progression and increased non-l iver morbidity and mortality beyond that already conferred by T2D alone.

also in 430 other papers